217 related articles for article (PubMed ID: 34895222)
1. Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells.
Bernard S; Poon AC; Tam PM; Mutsaers AJ
BMC Vet Res; 2021 Dec; 17(1):382. PubMed ID: 34895222
[TBL] [Abstract][Full Text] [Related]
2. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines.
Kent MS; Collins CJ; Ye F
Am J Vet Res; 2009 Feb; 70(2):263-9. PubMed ID: 19231960
[TBL] [Abstract][Full Text] [Related]
3. Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Poon AC; Inkol JM; Luu AK; Mutsaers AJ
J Vet Intern Med; 2019 Mar; 33(2):800-811. PubMed ID: 30556178
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
5. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
8. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
Inkol JM; Poon AC; Mutsaers AJ
Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.
Brockley LK; Cooper MA; Bennett PF
N Z Vet J; 2013 Jan; 61(1):25-31. PubMed ID: 22913610
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
Fowles JS; Denton CL; Gustafson DL
Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
13. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision.
Dank G; Rassnick KM; Sokolovsky Y; Garrett LD; Post GS; Kitchell BE; Sellon RK; Kleiter M; Northrup N; Segev G
Vet Comp Oncol; 2014 Mar; 12(1):78-84. PubMed ID: 22737988
[TBL] [Abstract][Full Text] [Related]
14. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
15. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitor everolimus reduces invasiveness of melanoma cells.
Ciołczyk-Wierzbicka D; Gil D; Zarzycka M; Laidler P
Hum Cell; 2020 Jan; 33(1):88-97. PubMed ID: 31586300
[TBL] [Abstract][Full Text] [Related]
17. The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention.
Chen YT; Tan KA; Pang LY; Argyle DJ
BMC Vet Res; 2012 May; 8():73. PubMed ID: 22647622
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.
Werzowa J; Cejka D; Fuereder T; Dekrout B; Thallinger C; Pehamberger H; Wacheck V; Pratscher B
Br J Dermatol; 2009 May; 160(5):955-64. PubMed ID: 19120326
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs.
Gordon IK; Ye F; Kent MS
Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
